• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188668 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

" U- S3 n+ v( S' y4 Z. p" ^可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  2 U# m* C1 f; M' x! }( H% b
6 S0 Z0 o) a; t+ h+ M$ P' h# p) [
5 j; N6 y6 M4 h* a
Sub-category:
0 e1 ]! e6 U. Y, jMolecular Targets
- ]* s, H9 V% O4 C$ j* a2 k, [& c6 |3 k& l. e; G3 s6 g: ]9 |2 N

- Y0 s/ j( N- k. ]+ W- nCategory:
' P; [; y0 L7 ^. c% t7 ATumor Biology
) s$ [3 @. t' f8 N8 U; k: g. N6 O5 U, Q& |7 z  ?. q
+ I, J; C, c# h+ d: s! s
Meeting:
( E6 f8 k. a/ m- F- P2011 ASCO Annual Meeting
6 J& I1 i2 ~/ D
! k6 A0 Y4 E$ l2 E& n+ A  ?; w. \" X; Z4 l
Session Type and Session Title:+ J5 r+ ^& |, H, _4 L9 f
Poster Discussion Session, Tumor Biology 6 @8 F$ p& h/ x4 i7 X, M1 I
; u; N0 l' N3 Z4 t/ l
: a: s  W3 z4 A3 L9 `0 N
Abstract No:
! v' f% c5 l: _! M% t6 r10517
" k8 `+ d6 G' b! W$ t: k) w: k; t5 W: P5 f& T6 |
+ N9 Z( H1 r' Q' N
Citation:5 F/ t0 N( W. e* x2 v/ c
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 m7 F' ?1 J( a
; Q( c- o8 R" z) i" i+ H2 s
0 f" {% h$ x4 k. i' E
Author(s):
) h" g+ |0 a2 l. OJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: n8 x9 w" N. z/ E: E! ]& _; a5 g
( A0 C! D  g. H
5 U* K9 d  G8 |" Y6 Q4 C0 ~3 y/ p- O* W6 D: b/ ]0 d
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.  Z$ Q9 y3 x, T2 T5 E

9 l3 a' O. T+ w! v3 f4 QAbstract Disclosures, g6 _8 ]7 V% v5 T1 F! _
. T* Y5 ?3 i) V( a' Q
Abstract:3 o9 p, z- V' W- v7 d4 m! w) T
& l, m# R4 w- M: e+ ?

4 j1 j+ F! g3 Z0 e8 v* Y: ]+ J3 aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
% F- }  \; g. G" Y/ ?! _3 G
' o2 ~. |% W. I7 z) T + q" Z  R% W, a7 O  ]$ a
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
6 }; }: r3 R" a, `* Y0 E, _没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
1 w" e8 B% Z- k7 f0 {! E/ z
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ( c" B' I+ Y2 O) d+ h2 }! m
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。0 A9 H, a0 q" R# I" t9 a3 D- C
ALK一个指标医院要900多 ...
% U% v! I" n$ t: s- i
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?" X' X! s- g( D% m, C

* p) [6 \9 n/ k+ |1 s3 f现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表